TECHNOLOGYPeripheral Blood Derived Parathyroid Hormone Receptor Positive Pluripotent Stem Cell Technology
Peripheral Blood Derived Parathyroid Hormone Receptor Positive Pluripotent Stem Cell Technology (“PTHR-PSC Technology”)
Tithon has been granted licenses to market and sell licenses to clinics and medical practices throughout the world (“Licensed Clinic Locations”), the PTHR-PSC Technology, including all products, methods, processes and procedures related to the ability to harvest, in therapeutic quantities, a distinct population of parathyroid hormone receptor positive pluripotent stem cells, initially isolated from adipose-tissue, but found in abundance in bone marrow, from where they originate, and present in peripheral blood, female ovarian follicular fluid and male seminal plasma. These cells express a unique marker that can be used to select them for both diagnostic and therapeutic procedures utilizing a proprietary antibody on its own or in combination with existing commercially available antibodies. These cells are in abundance in peripheral blood and in reproductive tissue secretions and dissipate in number and function in humans as they age. Tithon’s scientists, based on early clinical research, believe these characteristics suggest that these cells will play a significant role in future stem cell based therapeutic and regenerative applications in treating human degenerative medical conditions, requiring to the regeneration of various tissues within the ectoderm, endoderm and mesoderm cell layers, along with certain degenerative states. Furthermore, unlike bone marrow, or adipose tissue derived cells, the peripheral blood derived pluripotent stem cells Tithon has developed the ability to harvest from peripheral blood can be taken from healthy donors, as testing shows them to be non-immunogenic.
Tithon researchers, in collaboration with medical professionals and university researchers, have begun to observe substantial improvements in a number of degenerative medical conditions, through administration of the cells obtained through the PTHR-PSC Technology, using proprietary methods, processes and procedures developed by Tithon, including osteoarthritis, osteoporosis and osteopenia, cosmetic skin tissue (including the dermis resulting in hair growth), erectile dysfunction, ovarian function, uterine endometrial growth and rejuvenation, commonly reported symptoms of aging, diabetes, cognitive function and cancer.
MEDICAL CONDITION ENQUIRY
For further information regarding a medical condition in which the Peripheral Blood Derived Parathyroid Hormone Receptor Positive Pluripotent Stem Cell Technology may be useful, contact us by completing and sending the following form, and we will contact you as soon as possible.